Chiara Nicolazzo1, Gian Maria Busetto2, Francesco Del Giudice3, Isabella Sperduti4, Diana Giannarelli4, Angela Gradilone1, Paola Gazzaniga1, Ettore de Berardinis3, Cristina Raimondi1. 1. Dipartimento Medicina Molecolare, Sapienza Università di Roma, Rome, Italy. 2. Dipartimento Scienze Ginecologico-Ostetriche e Scienze Urologiche, Sapienza Università di Roma, Viale Regina Elena, 324, 00161, Rome, Italy. gianmaria.busetto@uniroma1.it. 3. Dipartimento Scienze Ginecologico-Ostetriche e Scienze Urologiche, Sapienza Università di Roma, Viale Regina Elena, 324, 00161, Rome, Italy. 4. Unità Biostatistica, Istituto Regina Elena, Rome, Italy.
Abstract
OBJECTIVES: Long-term follow-up study to evaluate the impact on disease-free survival and cancer-specific survival of survivin expression in tissue and CTCs from T1G3 bladder cancer patients. PATIENTS AND METHODS: The study was conducted using tumor tissue and blood samples from 54 patients with a primary diagnosis of T1G3 NMIBC. Survivin was evaluated by reverse transcription-polymerase chain reaction in tumor tissues. CTCs were isolated from blood by CELLection™ Dynabeads (Invitrogen, Carlsbad, CA, USA). Cells were lysed and cDNA was synthesized and analysed for the expression of CD45, CK8 and survivin. The endpoints of this long-termanalysis were disease-free survival, DFS and cancer-specific survival, CSS. RESULTS: Here, we report that, at 9 years of median follow-up, disease-free survival and cancer-specific survival are both significantly influenced by the expression of survivin in tumor tissue (p = 0.006), by the presence of CTCs (p < 0.0001) and by the expression of survivin in CTCs (p < 0.0001). CONCLUSION: The statistically significant impact of survivin expressing CTCs on cancer-specific survival that we observed might be interpreted as the result of the persistence of a subpopulation of highlander cells in the blood of T1G3 bladder patients over time.
OBJECTIVES: Long-term follow-up study to evaluate the impact on disease-free survival and cancer-specific survival of survivin expression in tissue and CTCs from T1G3 bladder cancerpatients. PATIENTS AND METHODS: The study was conducted using tumor tissue and blood samples from 54 patients with a primary diagnosis of T1G3 NMIBC. Survivin was evaluated by reverse transcription-polymerase chain reaction in tumor tissues. CTCs were isolated from blood by CELLection™ Dynabeads (Invitrogen, Carlsbad, CA, USA). Cells were lysed and cDNA was synthesized and analysed for the expression of CD45, CK8 and survivin. The endpoints of this long-termanalysis were disease-free survival, DFS and cancer-specific survival, CSS. RESULTS: Here, we report that, at 9 years of median follow-up, disease-free survival and cancer-specific survival are both significantly influenced by the expression of survivin in tumor tissue (p = 0.006), by the presence of CTCs (p < 0.0001) and by the expression of survivin in CTCs (p < 0.0001). CONCLUSION: The statistically significant impact of survivin expressing CTCs on cancer-specific survival that we observed might be interpreted as the result of the persistence of a subpopulation of highlander cells in the blood of T1G3 bladder patients over time.
Authors: Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan Journal: Eur Urol Date: 2012-07-25 Impact factor: 20.096
Authors: Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth Journal: Eur Urol Date: 2006-01-17 Impact factor: 20.096
Authors: Angela Gradilone; Arianna Petracca; Chiara Nicolazzo; Walter Gianni; Enrico Cortesi; Giuseppe Naso; Bruno Vincenzi; Cristiano Cristini; Ettore De Berardinis; Franco Di Silverio; Anna Maria Aglianò; Paola Gazzaniga Journal: BJU Int Date: 2010-09 Impact factor: 5.588
Authors: Vittorio Fasulo; Marco Paciotti; Massimo Lazzeri; Roberto Contieri; Paolo Casale; Alberto Saita; Giovanni Lughezzani; Pietro Diana; Nicola Frego; Pier Paolo Avolio; Piergiuseppe Colombo; Grazia Maria Elefante; Giorgio Guazzoni; Nicolò Maria Buffi; Michael Bates; Rodolfo Hurle Journal: Front Oncol Date: 2022-01-27 Impact factor: 6.244
Authors: Gian Maria Busetto; Daniele D'Agostino; Michele Colicchia; Katie Palmer; Walter Artibani; Alessandro Antonelli; Lorenzo Bianchi; Aldo Bocciardi; Eugenio Brunocilla; Marco Carini; Giuseppe Carrieri; Luigi Cormio; Ugo Giovanni Falagario; Ettore De Berardinis; Alessandro Sciarra; Costantino Leonardo; Francesco Del Giudice; Martina Maggi; Ottavio de Cobelli; Matteo Ferro; Gennaro Musi; Amelio Ercolino; Fabrizio Di Maida; Andrea Gallina; Carlo Introini; Ettore Mearini; Giovanni Cochetti; Andrea Minervini; Francesco Montorsi; Riccardo Schiavina; Sergio Serni; Claudio Simeone; Paolo Parma; Armando Serao; Mario Salvatore Mangano; Giorgio Pomara; Pasquale Ditonno; Alchiede Simonato; Daniele Romagnoli; Alessandro Crestani; Angelo Porreca Journal: Front Oncol Date: 2022-05-05 Impact factor: 5.738
Authors: Eila C Skinner; Ettore De Berardinis; Francesco Del Giudice; Gian Maria Busetto; Martin S Gross; Martina Maggi; Alessandro Sciarra; Stefano Salciccia; Matteo Ferro; Isabella Sperduti; Simone Flammia; Vittorio Canale; Benjamin I Chung; Simon L Conti; Michael L Eisenberg Journal: J Cancer Res Clin Oncol Date: 2021-03-06 Impact factor: 4.553